Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15050831 | 0.83 | ALDH1A1 (0.31) | SMN1; SMN2L3MBTL1MAPTALDH1A1KDM4E | |
| SCHEMBL15051241 | 0.81 | P2RX7 (0.35) | P2RX7DGAT1MAPK14 | |
| SCHEMBL15072587 | 0.77 | DGAT1 (0.34) | P2RX7SMN1; SMN2DGAT1ALDH1A1KDM4E | |
| SCHEMBL15051315 | 0.77 | DGAT1 (0.33) | P2RX7SMN1; SMN2DGAT1MAPT | |
| SCHEMBL15051765 | 0.74 | DGAT1 (0.30) | P2RX7DGAT1 | |
| SCHEMBL627420 | 0.71 | PIK3C3 (0.33) | P2RX7DGAT1MAPT | |
| SCHEMBL15050992 | 0.71 | SMN1; SMN2 (0.35) | SMN1; SMN2MAPK14MAPT | |
| SCHEMBL626741 | 0.70 | P2RX7 (0.35) | P2RX7DGAT1MAPTALDH1A1 | |
| SCHEMBL15051324 | 0.69 | DGAT1 (0.32) | DGAT1GAA | |
| SCHEMBL15051049 | 0.68 | KDM4E (0.36) | SMN1; SMN2L3MBTL1MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165464-A1 | HETEROARYLS AND USES THEREOF | PIK3C2B, PI4KB, PIK3R4 | P2RX7 1617/4885SMN1; SMN2 3783/4885L3MBTL1 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.